10.06.2015
amp biosimilars AG DE000A0SMU87
DGAP-News: amp biosimilars AG: Second biosimilar product successfully out-licensed
DGAP-News: amp biosimilars AG / Key word(s): Agreement/Joint Venture
amp biosimilars AG: Second biosimilar product successfully
out-licensed
10.06.2015 / 07:00
---------------------------------------------------------------------
amp biosimilars AG: Second biosimilar product successfully out-licensed
- Second successful out-licensing within brief period
- Leading position in Asia
- Potential earnings exceed hundreds of millions of euros
- Further out-licensing in pipeline
Hamburg, Germany, June 10, 2015 - amp biosimilars AG (ISIN: DE000A0SMU87),
a company focused on developing high quality biosimilars, is now able to
report a second successful out-licensing shortly after its first successful
biosimilar out-licensing. The second successfully out-licensed biosimilar
in the product pipeline is ABY-021, which is a humanized monoclonal
antibody for treating immunological symptoms.
The out-licensing partner is once again a leading medium-sized Chinese
pharmaceuticals company, which has thus secured the rights to market
ABY-021 in China. The licensing helps amp biosimilars to secure complete
financing for the development and approval processes starting from Clinical
Phase I on through to production and marketing of the biosimilar in China.
The global rights outside of China remain with amp biosimilars and allow
the issuance of further licenses to other pharmaceutical companies around
the world, creating potential for additional earnings.
In addition to the financing of product development up to the approval
process, amp biosimilars will receive royalties starting from the marketing
launch of the biosimilar, which may be worth hundreds of millions of euros.
"The second out-licensing in such a short period of time is a very
important milestone for amp biosimilars," explains Dr. Marc W. Hentz, Chief
Executive Officer of amp biosimilars AG. "Our partners are acknowledging
that our unique approach means we can develop biosimilars more affordably
and efficiently than any of our competitors and that we have wide-ranging
experience and the extensive technological skill in the biosimilar field.
In addition we are also confirming our decisive competitive advantage:
Strategic access to the fastest growing pharmaceuticals markets. Our
company can thus outpace growth on the overall market."
"This out-licensing is incredibly important for our company and a huge
success. The deal illustrates our importance in the market place and is
recognition of our business model as it differs from many competitors like
for example Coherus, Sandoz or Quintiles by focusing on 'pharmerging
markets'," adds Dr. Knut Adermann, Chief Technology Officer at amp
biosimilars AG. "It is an impressive sign that we have the unique
opportunity to grow faster than other market participants in this very
interesting segment."
amp biosimilars views this second out-licensing within a short period as
confirmation of the strategic focus with further transactions to follow
soon. The initial out-licensing of ABY-018, which amp biosimilars disclosed
a few weeks ago, provided shareholders with undiluted project financing up
to approval as well as cumulative earnings potential worth hundreds of
millions of euros. In addition, amp biosimilars will now have a leading
position on the Chinese biosimilars market, which will become the largest
in the world by 2017 and thus succeed Europe.
About biosimilars:
Biosimilars are imitations of existing bio-pharmaceuticals and constitute
one of the fastest growing segments of the pharmaceutical industry. Sales
are expected to increase in the next 10 years from the current 3 billion US
dollars to an estimated 100 billion US dollars. Biosimilars are more
affordable than original products and provide access to new therapies for a
far greater number of patients. Biosimilars represent potential savings of
250 billion US dollars by 2024 in the US healthcare system alone.
Biosimilars open new markets with significantly lower development risks
thanks to the use of well-known active ingredients.
About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand
on global therapeutic markets and is one of the most innovative and dynamic
biosimilar companies in Europe. The company is headquartered in Hamburg and
run by a team of leading industry experts. The development of a wide
variety of biosimilars will provide patients around the world with access
to life-improving and life-saving therapies. The combination of a research
platform with state-of-the-art analytics, process technology and clinical
expertise as well as regulatory know-how, makes amp biosimilars AG one of
the leading companies for biosimilar development and marketing. Thanks to
an international network of leading pharmaceutical companies, amp
biosimilars AG also has direct access to the strongest growing markets in
the world. With this approach amp biosimilars AG has a key position in one
of the fastest growing life science markets in the near future. amp
biosimilars AG has been listed on the Munich Stock Exchange since April 1,
2015. For more information please go to www.ampbiosimilars.com.
Contact:
MC Services AG
Fabian Lorenz
Tel: +49 211 529252-28
E-mail: [email protected]
---------------------------------------------------------------------
10.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
366827 10.06.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
amp biosimilars AG ISIN: DE000A0SMU87 können Sie bei EQS abrufen
IT-Infrastruktur , A0SMU8 , NB2 , XETR:NB2